Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

195.73USD
6:12pm GMT
Change (% chg)

$-0.68 (-0.35%)
Prev Close
$196.41
Open
$196.77
Day's High
$197.26
Day's Low
$195.24
Volume
352,277
Avg. Vol
1,166,004
52-wk High
$210.18
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 31.13 34.39
EPS (TTM): 11.00 -- --
ROI: 11.98 15.55 14.96
ROE: 26.43 16.92 16.52

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

04 Dec 2018

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc , updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

04 Dec 2018

UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Dec 3 Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

04 Dec 2018

Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track

SAN DIEGO Dec 3 Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

04 Dec 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

08 Nov 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

Nov 8 Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

08 Nov 2018

Amgen posts higher quarterly EPS, Repatha sales fall short

Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

30 Oct 2018

Amgen posts higher quarterly EPS, Repatha sales fall short

Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

30 Oct 2018

UPDATE 2-Amgen posts higher quarterly EPS, Repatha sales fall short

Oct 30 Amgen Inc on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

30 Oct 2018

Amgen quarterly net profit falls as expenses increase; EPS rises

Oct 30 Amgen Inc on Tuesday said its third quarter profit fell as higher expenses offset a lower tax rate and price concessions kept sales of its cholesterol drug Repatha below Wall Street estimates.

30 Oct 2018

Earnings vs. Estimates